http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc#Head http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc#assertion http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc#provenance http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc#pubinfo http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc#assertion http://purl.obolibrary.org/obo/DOID_2983 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_2983 http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00698 http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc#association http://www.w3.org/2000/01/rdf-schema#label "Anuria, oliguria, or significant impairment of renal function (creatinine clearance under 60 mL per minute or clinically significant elevated serum creatinine) are contraindications. Treatment of this type of patient carries an increased risk of toxicity because of impaired excretion of the drug. Because of the possibility of hemolytic anemia due to immature erythrocyte enzyme systems (glutathione instability), the drug is contraindicated in pregnant patients at term (38 to 42 weeks gestation), during labor and delivery, or when the onset of labor is imminent. For the same reason, the drug is contraindicated in neonates under one month of age. Nitrofurantoin Capsules, USP (monohydrate/ macrocrystals) are contraindicated in patients with a previous history of cholestatic jaundice/hepatic dysfunction associated with nitrofurantoin. Nitrofurantoin Capsules, USP (monohydrate/ macrocrystals)are also contraindicated in those patients with known hypersensitivity to nitrofurantoin." http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc#association https://w3id.org/biolink/vocab/relation https://schema.org/MedicalContraindication https://identifiers.org/drugbank:DB00698 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc#provenance http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc#pubinfo http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc#sig http://purl.org/nanopub/x/hasSignature ARdH/F/MUf6zo7jk7XyW0mn4JtOIrAvNJ+cpkXcqs5qsjk/zOFTxn25Lol1X2uYcUqA5ZBYoL07KYoeO3NLXIexXVye8U2dHJ8/YIIIH+J3PkveG4cHem5GihVkP2Rk2HqobMmNMwquPAYtx5wdEH3bdsTjPDDnybnSYUmnB2oc= http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc http://purl.org/dc/terms/created 2021-08-23T18:29:20.442+02:00 http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RALJFXlSsIHYEH-GA3sofURK7ZEmxLVyAfsPUrhZh5Shc https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY